MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses

MacroGenics stock ticked up 3.4% to US$4.22 into the weekend, a modest relief move for a biotech that has been grinding through loss-making quarters and a choppy three month stretch. The headline from this earnings release is not the top line; it is the size of the earnings drag. MacroGenics reported a quarterly loss of US$69.6 million from ongoing operations and basic earnings per share of US$1.10 in the red. For anyone thinking beyond today’s small bounce, the real question is how long this margin squeeze can be funded before the story has to change.

Love the science behind MacroGenics but concerned about the ongoing losses and earnings drag? You may want to consider 80 resilient stocks with low risk scores if you are looking for stocks that pair resilience with stronger fundamentals and lower risk profiles.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$32.832 million vs. US$6.869 million (higher quarterly revenue)
• Net Loss, Q2 2026 vs. Q2 2025: US$69.642 million loss vs. US$42.717 million loss (wider quarterly loss)
• Basic EPS, Q2 2026 vs. Q2 2025: US$1.10 loss per share vs. US$0.68 loss per share (larger loss per share)
• Earnings from Discontinued Operations, Q2 2026 vs. Q2 2025: US$89.157 million vs. US$6.466 million (much higher discontinued contribution)

Tired of scrolling through dense earnings tables and raw MacroGenics figures? See the full financial picture in an easy visual format that highlights the company’s earnings profile and recent results in the company report for MacroGenics.

MacroGenics bull story leans on revenue proof

Bulls argue that MacroGenics can use its antibody and ADC oncology platforms to convert partnerships and milestones into a steadier revenue base while keeping funding intact through the clinic. The Q2 2026 print gives partial support. Revenue of US$32.832 million versus US$6.869 million a year ago lines up with the idea that deal driven income can be meaningful, and the US$89.157 million from discontinued operations shows the company can monetize assets when needed. That helps offset ongoing cash burn in the short term. However, the wider quarterly net loss of US$69.642 million and a basic loss per share of US$1.10 show that cost discipline and margin repair have not yet caught up with the revenue story. The small 3.4% share price move into the weekend suggests investors see progress, but not a completed bull playbook.

Bear case tests MacroGenics cash burn worries

Bears frame MacroGenics as a company with lumpy milestone revenue, no product base and a habit of funding large R&D and operating costs through shareholders. The latest earnings support several of those concerns. Revenue is heavily influenced by deal and discontinued items, with US$89.157 million from discontinued operations towering over the US$32.832 million from continuing activity. Core operations still produced a quarterly loss of US$69.642 million and a larger US$1.10 loss per share versus last year, which points to ongoing financial strain rather than improvement. The stock is down 6.0% over 30 days and 3.0% over 90 days, even after a 3.4% bounce post report. That price action is consistent with investors continuing to price in dilution risk and execution uncertainty while giving limited credit so far for the pipeline and partnership narrative.

After repeated losses and earnings pressure, are MacroGenics cash burn and deal driven revenue just the visible issues? Review the independent risk analysis for MacroGenics which shows 2 important warning signs

Stay Ahead With Simply Wall St

If MacroGenics earnings swings and cash burn have your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch for a more attractive entry point. Once you are invested, use the Portfolio Command Center to cut through market noise and keep on top of the most important developments for your holdings. For a broader view, tap into crowd insights and shared research through the Community to see how other investors are thinking about opportunities and risks. By spotting potential catalysts and pressure points early, you can act with more confidence and stay a step ahead of the market.

Seeking Alternatives Beyond MacroGenics Now

Fresh ideas do not stay under the radar for long. Stocks can move from quiet to breakout quickly. Scan new momentum while it matters and look to enter positions early.

• Identify sturdy companies where balance sheets support the story and earnings remain stable. Then focus on the curated list of solid balance sheet and fundamentals stocks (51 results) before others catch on.
• Look for potential income momentum from companies that currently pay higher yields by scanning the hand picked 10 dividend fortresses while prices and payouts still appear aligned.
• Seek growth where profits already exist, not just promises, by scanning the focused list of 75 profitable AI stocks that aren't just burning cash before the broader market pushes valuations higher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com